IP Library Granted Patent US 10,166,384
Granted Patent B2
US 10,166,384 · App. 15/822,580 · Granted Jan 1, 2019

Systems and methods for treating shoulder pain related to subacromial impingement syndrome

Inventors: Maria E. Bennett (Beachwood, OH); Joseph W. Boggs, II (Chapel Hill, NC); John Chae (Strongsville, OH)
Assignee: SPR Therapeutics, Inc.
A61N1/0504A61N1/025A61N1/0502A61N1/0551A61N1/08A61N1/36071A61N1/0456
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,166,384
App. No.
15/822,580
Granted
Jan 1, 2019
Kind
B2
Abstract

Systems and methods are provided for treating chronic pain occurring secondarily to subacromial impingement syndrome in a human body. A system is provided to deliver percutaneous electrical stimulation through at least one electrode to neurological motor points of the posterior and middle deltoid muscles to mediate such pain. One-time, continued and/or periodic dosing of treatment methods according to the present invention may result in a change to central nervous system maladaptive neuroplasticity.

Claims (34)

1. A method comprising the steps of:

placing an electrode in subepidermal tissue of a human; and

delivering electrical stimulation through the electrode,

wherein, after the delivering step, a level of pain perceived by the human, wherein the pain was caused by or occurring secondarily to subacromial impingement syndrome, is reduced, and

wherein during the delivering step, a level of pain perceived by the human, wherein the pain was caused by or occurring secondarily to subacromial impingement syndrome, is reduced.

2. An electrical stimulation system comprising:

a percutaneous electrical lead;

an electrode insertable into subepidermal tissue of a patient, the electrode operatively coupled with the lead;

an electrical stimulator operatively coupled with the percutaneous electrical lead, wherein the electrical stimulator delivers electrical stimulation through the electrode to produce a muscle contraction in a target area and to alter maladaptive neuroplasticity in a central nervous system of the patient whereby a therapeutic effect is produced.

3. The electrical stimulation system of claim 2 , wherein the electrode is formed as part of the lead.

4. The electrical stimulation system of claim 2 , wherein the electrode extends from a conductor attached with the lead.

5. The electrical stimulation system of claim 2 , wherein the lead includes a portion having an insulated body and the electrode is formed from a portion of the lead free of the insulated body.

6. The electrical stimulation system of claim 2 , wherein the electrical stimulator is external to the patient.

7. The electrical stimulation system of claim 2 further comprising a cable having a first connector element operatively attached to the electrical stimulator and a second connector operatively attached to the lead.

8. The electrical system of claim 2 , wherein the electrode comprises an extension and a barb.

9. The electrical system of claim 8 further comprising an introducer needle configured to percutaneously insert the lead.

10. The electrical system of claim 8 , wherein the barb is angled relative to the extension of an angle of about 20 degrees to 70 degrees.

11. The electrical system of claim 2 , wherein a parameter of the electrical stimulation delivered through the electrode comprises a frequency of between 5 HZ and 25 HZ.

12. The electrical system of claim 2 , wherein a parameter of the electrical stimulation delivered through the electrode comprises a pulse duration of between 20 microseconds and 200 microseconds.

13. The electrical system of claim 2 , wherein a parameter of the electrical stimulation delivered through the electrode comprises an amplitude of between 0.1 mA and 20 mA.

14. An electrical stimulation system comprising:

a percutaneous electrical lead;

an electrode insertable into subepidermal tissue of a patient, the electrode operatively coupled with the lead;

an electrical stimulator operatively coupled with the percutaneous electrical lead, wherein the electrical stimulator delivers electrical stimulation through the electrode to produce a muscle contraction in a target area and sustain functional reorganization of maladaptive neuroplastic changes of a nervous system of the patient associated with chronic pain.

15. The electrical system of claim 14 , wherein a parameter of the electrical stimulation delivered through the electrode comprises a frequency of between 5 HZ and 25 HZ.

16. The electrical system of claim 14 , wherein a parameter of the electrical stimulation delivered through the electrode comprises a pulse duration of between 20 microseconds and 200 microseconds.

17. The electrical system of claim 14 , wherein a parameter of the electrical stimulation delivered through the electrode comprises an amplitude of between 0.1 mA and 20 mA.

18. The electrical stimulation system of claim 14 , wherein the lead comprises a coiled wire portion that is insulated.

19. The electrical stimulation system of claim 18 , wherein the electrode is formed from a de-insulated portion of the lead and includes a coiled wire portion.

20. The electrical stimulation system of claim 14 , wherein the electrical stimulator is external to the patient.

21. The electrical system of claim 14 further comprising an introducer needle configured to percutaneously insert the lead.

22. The electrical system of claim 14 , wherein the electrode comprises an extension and a barb.

23. The electrical system of claim 22 , wherein the barb is angled relative to the extension of an angle of about 20 degrees to 70 degrees.

24. The electrical system of claim 14 further comprising a connector electrically and operatively connecting the lead with the electrical stimulator.

Assignments (4)
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 30, 2024
From: SPR THERAPEUTICS, INC.
To: SLR INVESTMENT CORP., AS AGENT
Reel/Frame 066381/0075 →
SECURITY INTEREST Recorded Jan 30, 2024
From: SPR THERAPEUTICS, INC.
To: GEMINO HEALTHCARE FINANCE, LLC
Reel/Frame 066412/0400 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2018
From: BENNETT, MARIA E.; BOGGS, JOSEPH W., II; CHAE, JOHN
To: SPR THERAPEUTICS LLC
Reel/Frame 047551/0360 →
CHANGE OF NAME Recorded Nov 20, 2018
From: SPR THERAPEUTICS, LLC
To: SPR THERAPEUTICS, INC.
Reel/Frame 048148/0644 →
Continuity (6)
Continuation 15202256 · Jul 5, 2016
Continuation 14536951 · Nov 10, 2014
Continuation 13991033
Provisional Application 61419537 · Dec 3, 2010
Provisional Application 61540934 · Sep 29, 2011
Related Publication 20180078756A1 · Mar 22, 2018
Cited By (3)
US 12,318,608 US 12,611,538 US 12,616,832